Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9499498 | 0.77 | RYR2 (0.47) | RYR2ALDH1A1HPGDGAA | |
| SCHEMBL19752486 | 0.77 | RYR2 (0.38) | RYR2ALDH1A1HPGD | |
| SCHEMBL2065238 | 0.77 | RYR2 (0.38) | RYR2TSHR | |
| SCHEMBL13864441 | 0.69 | ALDH1A1 (0.47) | RYR2ALDH1A1HPGDACHETSHR | |
| SCHEMBL15761043 | 0.69 | — | — | |
| SCHEMBL44494 | 0.67 | RYR2 (0.32) | RYR2ALDH1A1KDM4EHPGDACHE | |
| SCHEMBL29750990 | 0.67 | RYR2 (0.32) | RYR2ALDH1A1KDM4EHPGDACHE | |
| SCHEMBL23766 | 0.67 | — | — | |
| SCHEMBL1012871 | 0.65 | — | — | |
| SCHEMBL29387129 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0335375-B1 | ANTIHYPERLIPIDEMIC AND ANTIATHEROSCLEROTIC COMPOUNDS AND COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | claimed |
| US-4948806-A | N-2,6-DIALKYL-OR N-2,6-DIALKOXYPHENYL-N'-ARYLALKYLUREA | WARNER-LAMBERT COMPANY (US) | 1990-08-14 | — | — | US | claimed |
| EP-0335375-A2 | Antihyperlipidemic and antiatherosclerotic compounds and compositions | WARNER-LAMBERT COMPANY (US) | 1989-10-04 | — | — | EP | claimed |
| WO-2024010015-A1 | PYRIMIDINE DERIVATIVES | あすか製薬株式会社 | 2024-01-11 | — | — | WO | disclosed |
| CN-108137513-B | Pyrimidine derivatives | ASKA 制药株式会社 | 2022-03-01 | — | — | CN | disclosed |
| EP-3372589-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-3536692-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10710967-B2 | Pyrimidine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-05 | — | — | US | disclosed |
| EP-3536692-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3173413-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0481920-B1 | Benzoheterocyclylalkylaminoalkane diphosphonic acids | CIBA GEIGY AG (CH) | 1995-07-19 | — | — | EP | disclosed |
| US-5204334-A | Inhibition of calcium resorption; osteoporosis; Paget's disease; bone disorders | CIBA-GEIGY CORPORATION (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0481920-A1 | Benzoheterocyclylalkylaminoalkane diphosphonic acids | CIBA-GEIGY AG (CH) | 1992-04-22 | — | — | EP | disclosed |
| US-5030653-A | N-2,6-dialkyl- or n-2,6-dialkoxyphenyl-n-arylalkylurea compounds | WARNER-LAMBERT COMPANY (US) | 1991-07-09 | — | — | US | disclosed |
| US-4999373-A | Phenyl ureas or thioureas substituted with a xanthene or thioxanthene group | WARNER-LAMBERT COMPANY (US) | 1991-03-12 | — | — | US | disclosed |
| US-4948806-A | N-2,6-DIALKYL-OR N-2,6-DIALKOXYPHENYL-N'-ARYLALKYLUREA | WARNER-LAMBERT COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| US-4868210-A | PHENYL UREAS AND PHENYL THIOUREAS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071280-A1 | PYRIMIDINE DERIVATIVE | CXCR1, PTGS1, P2RY1 | RYR2 457/4885ALDH1A1 576/4885KDM4E 2806/4885 |
| US-10710967-B2 | Pyrimidine derivative | CXCR1, PTGS1, P2RY1 | RYR2 457/4885ALDH1A1 576/4885KDM4E 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.